VLS-01: A proprietary formulation of DMT, a rapid- and short-acting psychedelic, being developed...

Thu, Aug 15

Earlier this week we announced positive topline results from the Phase 1b trial of VLS-01 for patients with TRD. Read our co-CEO @SriniGRao's blog to learn how DMT works and what this could mean for patients https://t.co/WUB8hGtEVK

131132

With this series of weekly blog posts, I want to highlight our clinical compounds and illustrate why we are so excited about their potential in mental health indications. In case you missed it, see...

Discover